Skip to main content

Mahon Paul A's Form 4 filing

United Therapeutics Corp (UTHR) · filed Jan 21, 2022

Accession no.
0001104659-22-006488
Filed
Jan 21, 2022
Trade date
Jan 20, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.23M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mahon Paul ACIK 0001231589Officer (EVP & General Counsel)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 20, 2022Common StockMOption exerciseAcquired+1,094$111.00+$121,43431,463Direct
Jan 20, 2022Common StockMOption exerciseAcquired+4,906$111.00+$544,56636,369Direct
Jan 20, 2022Common StockSSaleDisposed−2,581$204.79F2−$528,562.9933,788Direct
Jan 20, 2022Common StockSSaleDisposed−1,709$205.82F3−$351,746.3832,079Direct
Jan 20, 2022Common StockSSaleDisposed−1,710$206.51F4−$353,132.130,369Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 20, 2022Common StockMOption exerciseDisposed−1,094$0.00$054,000Direct
Jan 20, 2022Common StockMOption exerciseDisposed−4,906$0.00$022,552Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $204.2050 to $205.19. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $205.24 to 206.2250. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $206.26 to $206.76. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)